By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
The Tech MarketerThe Tech MarketerThe Tech Marketer
  • Home
  • Technology
  • Entertainment
    • Memes
    • Quiz
  • Marketing
  • Politics
  • Visionary Vault
    • Whitepaper
Reading: What 2D Spatial Biology Is Leaving on the Table: The Next Dimension of Discovery: Advancing Spatial Biology in Three Dimensions – Stellaromics
Share
Notification Show More
Font ResizerAa
The Tech MarketerThe Tech Marketer
Font ResizerAa
  • Home
  • Technology
  • Entertainment
  • Marketing
  • Politics
  • Visionary Vault
  • Home
  • Technology
  • Entertainment
    • Memes
    • Quiz
  • Marketing
  • Politics
  • Visionary Vault
    • Whitepaper
Have an existing account? Sign In
Follow US
© The Tech Marketer. All Rights Reserved.
White Paper

What 2D Spatial Biology Is Leaving on the Table: The Next Dimension of Discovery: Advancing Spatial Biology in Three Dimensions – Stellaromics

thetechmarketer
Last updated:
thetechmarketer 18 minutes ago
Share
SHARE

INTRODUCTION

Spatial transcriptomics has fundamentally changed how researchers understand gene expression — but most platforms are still working in two dimensions. Traditional spatial biology methods rely on thin, 5-10 micrometer tissue slices that strip away the very context they set out to preserve: how cells are positioned relative to each other in three-dimensional space, how microenvironmental cues drive disease progression, and how tissue architecture shapes therapeutic response. The result is a systematic underrepresentation of cellular complexity that distorts everything from cell density measurements to spatial distance calculations to the detection of rare cell populations.

The transition from 2D to 3D spatial omics is not an incremental upgrade — it is a paradigm shift in what questions biology can ask and answer. This white paper from Stellaromics makes the scientific and practical case for 3D spatial biology, explains the foundational STARmap technology that enables it, and introduces the Pyxa platform as the first purpose-built system for delivering true 3D spatial multi-omics in thick tissue sections at subcellular resolution.


YOU WILL LEARN

  • Why thin 2D tissue sections systematically misrepresent cell density, spatial relationships, rare cell populations, and cell morphology — and what that costs downstream in research quality
  • How 3D spatial biology captures the full architecture of intact tissue volumes, including cellular diversity, spatial relationships, cell morphology, and subcellular molecular activity in a single workflow
  • What the STARmap sequencing technology does differently — and why its SEDAL approach (sequencing with error-reduction by dynamic annealing and ligation) enables RNA mapping with single-cell resolution inside 3D tissue
  • How cell density changes dramatically between 5 µm and 100 µm tissue sections — 4.25 versus 65.75 cells per 100 µm² — and what that means for the statistical power of spatial analyses
  • Published discovery applications of 3D spatial transcriptomics across neuroscience, oncology, developmental biology, and advanced therapeutic modalities including CRISPR and CAT-T
  • How the Pyxa platform integrates kit-based sample preparation, confocal volumetric imaging, GPU-enabled signal processing, and PyxaStudio software into a streamlined end-to-end workflow
  • What subcellular resolution means in practice: detecting hundreds of RNAs in situ with XYZ coordinates of each transcript within each cell, distinguishing cytosolic versus nuclear signal
  • Why scalability and automation matter for translating 3D spatial biology from exploratory research into reproducible multi-sample programs

Strategic Insight: The Third Dimension Is Not a Feature — It’s the Missing Data

2D Analysis Introduces Structural Bias at the Foundation
The white paper opens with a pointed argument: 2D spatial biology does not simply offer a simplified view of tissue — it actively misrepresents biological reality. Thin sectioning introduces four distinct failure modes: sampling bias (rare cells or essential features missed by thin slices), structural misrepresentation (large or complex cell structures obscured), distorted cell relationships (spatial distances and adjacency misrepresented in 2D projection), and disrupted cell morphology (serial sectioning shears cell layers). The data makes this concrete: analysis of healthy mouse brain tissue showed cell density of 4.25 cells/100 µm² in a standard 5 µm section versus 65.75 cells/100 µm² in a 100 µm section — a more than 15-fold difference — along with dramatically altered nearest-neighbor distances between cell types that only become visible in the third dimension.

STARmap Provides the Technical Architecture That Makes 3D Possible
Most spatial transcriptomics platforms were designed around the constraints of 2D thin sections and cannot physically operate at the tissue volumes required for true 3D analysis. STARmap solves this by mapping RNA transcripts with single-cell resolution directly within intact 3D tissue using SEDAL sequencing with hydrogel-embedding of amplicons — enabling in situ RNA sequencing in whole tissue volumes at subcellular resolution. Combined with transcriptomics, translatomics, and morphological analysis, the approach delivers a genuinely holistic view of biological systems that no 2D platform can replicate.

Discovery Applications Are Already Demonstrating 3D’s Scientific Advantage
The white paper documents published research outcomes across four domains. In neuroscience, 3D spatial transcriptomics has enabled whole-brain atlasing and cellular mapping across 3D neural networks, correlation of CNS gene expression with function and location, and rare neuronal network connectomics that 2D tissues miss entirely. In oncology and immuno-oncology, the technology captures rare cell-to-cell communication events in immunotherapy drug resistance, maps the spatial relationship between TILs and tumor cells to confirm TIL efficacy, and studies tumor evolution in 3D. In developmental biology, it reveals spatiotemporal patterns of cellular organization during tissue regeneration and preferential clustering of neural cell lineages. And for advanced therapeutic modalities — CRISPR, CAT-T, protein therapeutics — 3D enables tracking of rare edit events in vivo and measurement of local payload impact on gene expression, T-cell activation, and translation.


GOVERNANCE / CHALLENGES

Transitioning from established 2D spatial protocols to 3D workflows introduces meaningful operational complexity — thick tissue sections require specialized sample preparation, volumetric imaging infrastructure, and computational pipelines capable of handling the substantially larger datasets generated per sample. For teams running multi-sample programs or clinical translational studies, workflow standardization and reproducibility across tissue types become critical bottlenecks that cannot be solved by instrumentation alone. The computational demands of 3D are non-trivial: GPU-enabled signal processing is not optional at the data volumes produced by subcellular-resolution volumetric imaging, and analysis software must keep pace with the richer, more complex outputs that 3D data generates.


IMPLEMENTATION / STRATEGY

Stellaromics positions Pyxa as a purpose-built end-to-end solution designed to collapse the operational complexity of 3D spatial biology into a standardized, automated workflow. Kit-based sample preparation feeds into confocal volumetric imaging of tissue sections up to 100 µm thick, with GPU-enabled signal processing running on the instrument and PyxaStudio software providing integrated 3D visualization and analysis. The platform is designed for compatibility with multiple tissue types and is optimized for both service and instrument workflows — allowing teams to access 3D spatial biology through a CRO relationship before committing to in-house instrumentation. The Pyxa architecture captures transcriptomics, translatomics, and morphology in a single run, with XYZ coordinates preserved for every detected transcript, making downstream spatial analysis richer from the first experiment.


WHO SHOULD READ THIS

This white paper is essential reading for spatial biology researchers, genomics platform decision-makers, and translational science leaders evaluating whether their current spatial transcriptomics approach is capturing the full biology of their tissue models. It is directly relevant to teams working in neuroscience, oncology, immuno-oncology, and cell and gene therapy who are encountering the limitations of thin-section spatial data, and for core facility directors assessing next-generation spatial platforms for multi-user and multi-program environments.


FINAL CTA

Download The Next Dimension of Discovery: Advancing Spatial Biology in Three Dimensions from Stellaromics to understand the scientific and technical case for 3D spatial biology, see the data comparing 2D versus 3D tissue analysis, and learn how the Pyxa platform delivers subcellular-resolution spatial multi-omics in intact tissue volumes.

You Might Also Like

Disconnected Systems Are Costing You More Than You Think: The Operations Health Check for Canadian Manufacturers – Odoo

Buying Smart, Not Just Buying Big: Biopharma Guide: Future-Proof Your Confocal Microscopy Platform Investment – Leica Microsystems

From 85% to 88% OTIF — and Climbing: National DCP: How ORTEC supports a scalable national supply chain – ORTEC

Rethinking the Last Mile: 5 steps to improve service and efficiency in store delivery – ORTEC

Precision Ultramicrotomy: Application-Driven Innovations for Sectioning Resin-Embedded Samples

Share This Article
Facebook LinkedIn Email Copy Link Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Tasty Chick'n LLC bankruptcy affects 84 KFC restaurants Tasty Chick’n LLC Bankruptcy: KFC Franchisee With 84 Restaurants Files Chapter 11
Leave a comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

Latest News

  • Grand Theft Auto VI has arrived

    More than a decade after Grand Theft Auto V was first released, its sequel is finally launching. On November 19th, GTA VI will be available on both the PS5 and Xbox Series X / S, and it’s quite possibly the most anticipated video game launch of all time. Part of this has to do with

  • ‘It’s a risk’: How Rockstar built the most detailed (and romantic) GTA yet

    Grand Theft Auto VI isn't just the biggest GTA game to date; it's also the most romantic. Though the series is well known for its sordid assortment of criminal leads, GTA VI switches things up by starring a pair of thieves who also happen to fall in love after meeting while stealing a car. It's

  • Grand Theft Auto VI does something impossible — it lives up to the hype

    How do you follow a game like Grand Theft Auto V? Thirteen years ago, Rockstar's crime-fueled epic went on to redefine what an open-world game could be and became an enormous success, selling more than 230 million copies across three generations of game consoles. It sits just behind Tetris and Minecraft on the list of

  • Satya Nadella says he’s AGI-pilled now

    Microsoft CEO Satya Nadella says he's AGI-pilled, at least when it comes to how AI might make startling changes to the structure of the economy and how politics might change because of it. "I am AGI-pilled in the sense that at an economy level, what is the political economy's organization around AGI?" he asked at

  • Jeff Bezos says he was ‘heavily involved’ in picking the new James Bond

    Robert Pattinson's casting as James Bond made enough sense given his recent work with director Denis Villeneuve, who's making the franchise's next film over at Amazon. But it turns out that Amazon founder Jeff Bezos played a significant role in making the final decision, too. During Semafor's Silicon Valley and the World conference today, Bezos

- Advertisement -
about us

We influence 20 million users and is the number one business and technology news network on the planet.

Advertise

  • Advertise With Us
  • Newsletters
  • Partnerships
  • Brand Collaborations
  • Press Enquiries

Top Categories

  • Artificial Intelligence
  • Technology
  • Bussiness
  • Politics
  • Marketing
  • Science
  • Sports
  • White Paper

Legal

  • About Us
  • Contact Us
  • Privacy Policy
  • Affiliate Disclaimer
  • Legal

Find Us on Socials

The Tech MarketerThe Tech Marketer
© The Tech Marketer. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?